Tanabe Hiroki, Mizukami Yusuke, Takei Hidehiro, Tamamura Nobue, Omura Yuhi, Kobayashi Yu, Murakami Yuki, Kunogi Takehito, Sasaki Takahiro, Takahashi Keitaro, Ando Katsuyoshi, Ueno Nobuhiro, Kashima Shin, Yuzawa Sayaka, Hasegawa Kimiharu, Sumi Yasuo, Tanino Mishie, Fujiya Mikihiro, Okumura Toshikatsu
Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan.
Department of Diagnostic Pathology, Asahikawa Medical University Hospital, Asahikawa Medical University, Asahikawa, Japan.
J Pathol Clin Res. 2021 Jul;7(4):397-409. doi: 10.1002/cjp2.209. Epub 2021 Mar 22.
Gastric cancer is a heterogenous disease with different phenotypes, genotypes, and clinical outcomes, including sensitivity to treatments and prognoses. Recent medical advances have enabled the classification of this heterogenous disease into several groups and the consequent analysis of their clinicopathological characteristics. Gastric cancer associated with Epstein-Barr virus (EBV) and microsatellite-unstable tumors are considered to be the two major subtypes as they are clearly defined by well-established methodologies, such as in situ hybridization and polymerase chain reaction-based analyses, respectively. However, discrepancies in the histological diagnosis of gastric neoplasms remain problematic, and international harmonization should be performed to improve our understanding of gastric carcinogenesis. We re-evaluated Japanese cases of early gastric cancer according to the current World Health Organization (WHO) criteria and classified them into genomic subtypes based on microsatellite instability (MSI) and EBV positivity to determine the initial genetic events in gastric carcinogenesis. A total of 113 Japanese early gastric cancers (including low- and high-grade dysplasias) treated with endoscopic resection over 5 years were archived in our hospital. A histological re-evaluation according to the WHO criteria revealed 54 adenocarcinomas, which were divided into 6 EBV-positive (11.1%), 7 MSI-high (MSI-H, 13.0%), and 41 microsatellite stable cases (75.9%). MSI-H adenocarcinoma was confirmed by an immunohistochemistry assay of mismatch repair proteins. Programmed death-ligand 1 immunostaining with two antibodies (E1L3N and SP263) was positive in tumor cells of one MSI-H adenocarcinoma case (1/7, 14.3%). The proportion of stained cells was higher with clone SP263 than with E1L3N. Histologically, EBV-positive carcinomas were poorly differentiated (83.8%), and MSI-H cancers were frequent in well to moderately differentiated adenocarcinoma (85.7%), indicating that the EBV-positive subtype presented with high-grade morphology even when an early lesion. Our study indicates that the WHO criteria are useful for subdividing Japanese early gastric cancers, and this subdivision may be useful for comparative analysis of precursor lesions and early carcinoma.
胃癌是一种具有不同表型、基因型和临床结局(包括对治疗的敏感性和预后)的异质性疾病。最近的医学进展使得能够将这种异质性疾病分为几组,并进而分析其临床病理特征。与爱泼斯坦-巴尔病毒(EBV)相关的胃癌和微卫星不稳定肿瘤被认为是两种主要亚型,因为它们分别通过成熟的方法(如原位杂交和基于聚合酶链反应的分析)得到明确界定。然而,胃肿瘤组织学诊断中的差异仍然存在问题,应进行国际协调以增进我们对胃癌发生的理解。我们根据世界卫生组织(WHO)现行标准对日本早期胃癌病例进行了重新评估,并根据微卫星不稳定性(MSI)和EBV阳性将它们分为基因组亚型,以确定胃癌发生中的初始遗传事件。我院存档了5年间接受内镜切除治疗的113例日本早期胃癌(包括低级别和高级别发育异常)。根据WHO标准进行的组织学重新评估显示有54例腺癌,其中分为6例EBV阳性(11.1%)、7例微卫星高度不稳定(MSI-H,13.0%)和41例微卫星稳定病例(75.9%)。通过错配修复蛋白的免疫组织化学检测确认了MSI-H腺癌。使用两种抗体(E1L3N和SP263)进行的程序性死亡配体1免疫染色在1例MSI-H腺癌病例(1/7,14.3%)的肿瘤细胞中呈阳性。克隆SP263染色的细胞比例高于E1L3N。组织学上,EBV阳性癌分化差(83.8%),MSI-H癌常见于高分化至中分化腺癌(85.7%),这表明即使是早期病变,EBV阳性亚型也呈现高级别形态。我们的研究表明,WHO标准对于细分日本早期胃癌很有用,这种细分可能有助于对癌前病变和早期癌进行比较分析。